Therapeutics News

NEPTUNE, N.J. – Anu Laul, OD, FAAO, shares a case of a patient experiencing long-term ocular nerve pain despite healing of the corneal surface after a cleaning device exploded on his face and eyes.

Nonselective systemic -blocker intake showed a clinically relevant association and a borderline significant trend with IOP decrease, while the use of cardioselective -blockers and all other cardiovascular medication did not, according to researchers.

BALTIMORE – Researchers found high levels of antibiotic resistance among staphylococci, along with many isolates demonstrating multidrug resistance, in preliminary results for ocular isolates collected in 2016 under the ARMOR program, presented at the Association of Research in Vision and Ophthalmology annual meeting.

The FDA has accepted the New Drug Application for brimonidine tartrate ophthalmic solution and set a PDUFA action date for Dec. 27, according to a press release from Valeant Pharmaceuticals and Bausch + Lomb.

Patients with noninfectious uveitis are at a high risk of IOP elevation, according to a large retrospective study.

Researchers report that vitamin E loading could effectively increase the amount of ciprofloxacin binding in commercial silicone-based soft contact lenses and sustain the release time in artificial tears, according to a study in Eye & Contact Lens.

Male sex, high myopia, higher central corneal thickness, lower K value, corneal haze, type of steroid used and length of therapy were associated with a higher risk of steroid-induced ocular hypertension after PRK surgery, a study showed.

The first U.S. patient has been enrolled in a phase 3 clinical trial for Shire’s SHP640, a combination broad-spectrum antiseptic and corticosteroid being evaluated for treating infectious keratitis in adults and children.

The announcement that Johnson & Johnson acquired Abbott Medical Optics for just more than $4 billion was the latest in a series of acquisitions and sales of surgical device companies in the past couple of years.

Four weeks of treatment with lifitegrast 5% ophthalmic solution in patients with dry eye disease resulted in subjective relief of symptoms, according to a recently published study.